Table 5.
Groups | Dose (IU/kg) | Cmax (mU/L) | Tmax (min) | AUC 0–120 min (mU/L × h) | BA (%) |
---|---|---|---|---|---|
INS-SOL (S.C.) | 1 | 11.1 ± 1.1 | 36.7 ± 12.0 | 16.2 ± 2.6 | 100 |
INS-LANano (I.N.) | 2 | 14.3 ± 2.7 * | 12.5 ± 2.2 | 11.3 ± 0.9 | 23.3 ± 1.8 *,** |
INS-SEN (I.N.) | 2 | 8.8 ± 2.6 | 10.0 ± 0.0 | 7.7 ± 0.3 | 15.8 ± 0.6 * |
INS-SOL (I.N.) | 2 | 4.1 ± 0.2 | 13.3 ± 3.3 | 3.4 ± 0.4 | 6.9 ± 0.8 |
Cmax: maximum plasma insulin concentration; Tmax: time to reach Cmax; AUC: area under the insulin concentration-time curve; I.N.: intranasal administration; SC: subcutaneous administration; BA: relative bioavailability compared with SC; Each value represents the mean ± SEM (n = 3–4); *: Significantly higher than INS-SOL (I.N.) **: Significantly higher than INS-SEN (I.N.); (p < 0.05).